Departments of Pathology and Laboratory Medicine.
Department of Anatomic Pathology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi.
Appl Immunohistochem Mol Morphol. 2022 Apr 1;30(4):257-263. doi: 10.1097/PAI.0000000000000996.
Metanephric adenoma (MA) and Wilms tumor (WT) represent 2 prototypes of primary renal neoplasms closely resembling embryonal renal tubules. Tumors with overlapping features may occur, requiring differential diagnoses between the 2. Evidence of divergent oncogenic pathways has been reported, suggesting that MA is driven by BRAF mutation while most WT is of the BRAF wild-type. We collected 4 MA cases, 3 cases of monophasic epithelial WT, and 1 overlap metanephric tumor that contains both conventional MA and high-grade components similar to epithelial WT. Whole-exome sequencing and whole transcriptome sequencing were performed to discover mutations, somatic copy number variation, and differential expression. The findings were compared with those of WT of the TARGET database (WT-TARGET). BRAF V600E mutation was detected in all MAs as well as the overlap tumor but was undetectable in all epithelial WTs and WT-TARGET. The overlap tumor showed an additional pathogenic mutation of SETD2. Three frequent gene mutations observed in WT-TARGET were not common in epithelial WT, in which the mutations appeared sporadic. The profiles of recurrent copy number variations were all different among MA, epithelial WT, and WT-TARGET. Differential expression and unsupervised hierarchical cluster analyses revealed distinct clusters of the 3 categories. Remarkably, the overlap tumor coclustered with MA, separated from epithelial WT and WT-TARGET. The distinctiveness of MA and WT were demonstrated corresponding to BRAF-mutated and non-BRAF-mutated pathways from the molecular perspective. BRAF assay has diagnostic implication for overlap tumors.
后肾腺瘤 (MA) 和肾母细胞瘤 (WT) 代表了两种紧密类似于胚胎肾小管的原发性肾肿瘤原型。具有重叠特征的肿瘤可能会发生,需要对这两种肿瘤进行鉴别诊断。已经报道了具有不同致癌途径的证据,表明 MA 由 BRAF 突变驱动,而大多数 WT 是 BRAF 野生型。我们收集了 4 例 MA 病例、3 例单相上皮 WT 病例和 1 例重叠性后肾母细胞瘤,该肿瘤包含常规 MA 和类似于上皮 WT 的高级别成分。进行了全外显子组测序和全转录组测序以发现突变、体细胞拷贝数变异和差异表达。将这些发现与 TARGET 数据库中的 WT(WT-TARGET)进行比较。所有 MA 以及重叠性肿瘤中均检测到 BRAF V600E 突变,但所有上皮 WT 和 WT-TARGET 中均未检测到。重叠性肿瘤显示出 SETD2 的另外一个致病性突变。在 WT-TARGET 中观察到的 3 个常见基因突变在上皮 WT 中并不常见,这些突变似乎是散发性的。MA、上皮 WT 和 WT-TARGET 之间的反复出现的拷贝数变异谱均不同。差异表达和无监督层次聚类分析揭示了这 3 个类别之间的不同聚类。值得注意的是,重叠性肿瘤与 MA 共同聚类,与上皮 WT 和 WT-TARGET 分离。从分子角度证明了 MA 和 WT 的独特性对应于 BRAF 突变和非 BRAF 突变途径。BRAF 检测对重叠性肿瘤具有诊断意义。